title: Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab.
authors.forename: Anna
authors.initials: A
authors.lastname: Balato
authors.forename: Nicola
authors.initials: N
authors.lastname: Balato
authors.forename: Cataldo
authors.initials: C
authors.lastname: Patruno
authors.forename: Lucia
authors.initials: L
authors.lastname: Gallo
authors.forename: Fabio
authors.initials: F
authors.lastname: Ayala
mesh_terms: D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000008:administration & dosage* / Q000009:adverse effects*; D004175:Diptera; D004359:Drug Therapy, Combination; D006801:Humans; D007891:Leishmania / Q000276:immunology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008297:Male; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; C472181:efalizumab